I-MAB (IMAB) PensionAndRetirementBenefit : $0.00 Mil (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB PensionAndRetirementBenefit?

I-MAB's PensionAndRetirementBenefit for the quarter that ended in Jun. 2023 was $0.00 Mil.

I-MAB PensionAndRetirementBenefit Historical Data

The historical data trend for I-MAB's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB PensionAndRetirementBenefit Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

PensionAndRetirementBenefit

Get a 7-Day Free Trial

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
PensionAndRetirementBenefit	Get a 7-Day Free Trial								-	-	-	-	-

I-MAB PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » PensionAndRetirementBenefit

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.